Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CLOSANTEL (AS CLOSANTEL SODIUM DIHYDRATE PH. EUR.)
Elanco Animal Health, Eli Lilly and Company Limited
QP52AG09
CLOSANTEL (AS CLOSANTEL SODIUM DIHYDRATE PH. EUR.)
50 Mg/Ml
Solution for Injection
LM: Licensed Merchant as defined in relevant national legislation
Cattle
closantel
Endoparasiticide
Authorised
2012-10-12
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Flukiver 50 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE Closantel (as Closantel sodium) 50 mg/ml EXCIPIENTS For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES TREMATODES _Fasciola hepatica_ _Fasciola gigantica_ NEMATODES _Haemonchus placei_ _Bunostomum phlebotomum_ _Oesophagostomum radiatum_ ARTHROPODS _Hypoderma bovis_ _Hypoderma lineatum_ 4.3 CONTRAINDICATIONS None. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _1_ _/_ _0_ _3_ _/_ _2_ _0_ _1_ _7_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _5_ _8_ _0_ _6_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Do not exceed the stated dose. Care should be taken to ensure that all injection procedures are correctly carried out and body weights accurately assessed. Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: - Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. - Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device. Suspected clinical cases of resistance to anthelmintics shoul Read the complete document